OliX Pharmaceuticals, Inc (KOSDAQ:226950)

South Korea flag South Korea · Delayed Price · Currency is KRW
148,200
-3,000 (-1.98%)
May 20, 2026, 3:30 PM KST
Market Cap3.01T +192.6%
Revenue (ttm)14.67B +158.3%
Net Income-15.74B
EPS-800.46
Shares Out20.30M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume264,268
Average Volume292,040
Open147,500
Previous Close151,200
Day's Range140,700 - 154,400
52-Week Range34,500 - 217,000
Betan/a
RSI39.37
Earnings DateMar 27, 2026

About OliX Pharmaceuticals

OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkle product; and OLX106 for diabetic foot ulcer. Its products pipeline also comprise OLX301 for age-related macular degeneration retinal fibrosis; OLX304 for retinitis pigmentosa; OLX201 for lung fibrosis;... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 226950
Full Company Profile

Financial Performance

In 2025, OliX Pharmaceuticals's revenue was 14.67 billion, an increase of 158.35% compared to the previous year's 5.68 billion. Losses were -15.74 billion, -61.28% less than in 2024.

Financial Statements